ASH 2014: Phase II study shows that blinatumomab achieves minimal residual disease response in acute lymphoblastic leukaemia

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Nicola Gökbuget (University Hospital Frankfurt, Frankfurt, Germany) presents the results of the single-arm phase II study that evaluated the Bispecific T-Cell Engager (BiTE) antibody construct (anti-CD19) blinatumomab in patients with minimal residual disease B-precursor acute lymphoblastic leukaemia.